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A B S T R A C T
Background
Crohn’s disease is a chronic relapsing condition of the alimentary tract with a high morbidity secondary to bowel inﬂammation.
Glutamine plays a key role in maintaining the integrity of the intestinal mucosa and has been shown to reduce inﬂammation and
disease activity in experimental models of Crohn’s disease.
Objectives
To evaluate the efﬁcacy and safety of glutamine supplementation for induction of remission in Crohn’s disease.
Search methods
We searched the following databases from inception to November 15, 2015: MEDLINE, EMBASE, the Cochrane Central Register of
Controlled Trials, and the Cochrane IBD Group Specialised Register. Study references were also searched for additional trials. There
were no language restrictions.
Selection criteria
Randomised controlled trials (RCTs) that compared glutamine supplementation administered by any route to a placebo, active com-
parator or no intervention in people with active Crohn’s disease were considered for inclusion.
Data collection and analysis
Two authors independently extracted data and assessed the methodological quality of the included studies. The Cochrane risk of
bias tool was used to assess methodological quality. The primary outcome measure was clinical or endoscopic remission. Secondary
outcomes included intestinal permeability, clinical response, quality of life, growth in children and adverse events. Risk ratios and 95%
conﬁdence intervals were calculated for dichotomous outcomes. The overall quality of the evidence supporting the primary outcome
was evaluated using the GRADE criteria.
Main results
Two small RCTs (total 42 patients) met the inclusion criteria and were included in the review. One study (18 patients) compared four
weeks of treatment with a glutamine-enriched polymeric diet (42% amino acid composition) to a standard polymeric diet (4% amino
acid composition) with low glutamine content in paediatric patients (< 18 years of age) with active Crohn’s disease. The other study
(24 patients) compared glutamine-supplemented total parenteral nutrition to non-supplemented total parenteral nutrition in adult
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patients (> 18 years of age) with acute exacerbation of inﬂammatory bowel disease. The paediatric study was rated as low risk of bias.
The study in adult patients was rated as unclear risk of bias for blinding and low risk of bias for all other items. It was not possible to
pool data for meta-analysis because of signiﬁcant differences in study populations, nature of interventions, and the way outcomes were
assessed. Data from one study showed no statistically signiﬁcant difference in clinical remission rates at four weeks. Forty-four per cent
(4/9) of patients who received a glutamine-enriched polymeric diet achieved remission compared to 56% (5/9) of patients who received
a standard low-glutamine polymeric diet (RR 0.80, 95% CI 0.31 to 2.04). A GRADE analysis indicated that the overall quality of
evidence for this outcome was low due to serious imprecision (9 events). In both included studies, no statistically signiﬁcant changes
in intestinal permeability were found between patients who received glutamine supplementation and those who did not. Neither study
reported on clinical response, quality of life or growth in children. Adverse event data were not well documented. There were no serious
adverse events in the paediatric study. The study in adult patients reported three central catheter infections with positive blood cultures
in the glutamine group compared to none in the control group (RR 7.00, 95% CI 0.40 to 122.44).
Authors’ conclusions
Currently there is insufﬁcient evidence to allow ﬁrm conclusions regarding the efﬁcacy and safety of glutamine for induction of remission
in Crohn’s disease. Data from two small studies suggest that glutamine supplementation may not be beneﬁcial in active Crohn’s disease
but these results need to be interpreted with caution as they are based on small numbers of patients. This review highlights the need
for adequately powered randomised controlled trials to investigate the efﬁcacy and safety of glutamine for induction of remission in
Crohn’s disease.
P L A I N L A N G U A G E S U M M A R Y
Glutamine for treatment of active Crohn’s disease
What is Crohn’s disease?
Crohn’s disease is a chronic inﬂammatory disorder of the intestines which has periods of inactivity and periods when it ﬂares up. Crohn’s
disease can affect any part of the digestive tract, from the mouth to the anus. The most common symptoms of the disease include
abdominal pain, non-bloody diarrhoea and weight loss. When people with Crohn’s disease are experiencing symptoms of the disease
it is said to be ‘active’; periods when the symptoms stop are called ‘remission’.
What is glutamine?
Glutamine is an amino acid that plays a key role in maintaining the integrity of the intestinal mucosa (lining of the intestines) and
has been shown to reduce inﬂammation and disease activity in animal models of Crohn’s disease. It has therefore been suggested that
glutamine may reduce intestinal inﬂammation in people with Crohn’s disease.
What did the researchers investigate?
The researchers investigated whether glutamine is effective for inducing remission in people with active Crohn’s disease and whether
this treatment causes any harms (side effects). The researchers searched the medical literature up to November 15, 2015.
What did the researchers ﬁnd?
The researchers identiﬁed two randomised controlled trials (total 42 participants) that investigated the role of glutamine for the
treatment of active Crohn’s disease. One study (18 patients) compared four weeks of treatment with a glutamine-enriched polymeric
diet (42% amino acid composition) to a standard polymeric diet (4% amino acid composition) with low glutamine content in paediatric
patients (< 18 years of age) with active Crohn’s disease. Participants were encouraged to consume the diet orally. If this was not possible
the diet was administered via a ﬁne-bore nasogastric tube. The other study (24 participants) compared glutamine-supplemented total
parenteral nutrition (TPN) to non-supplemented TPN in adult patients (> 18 years of age) with sudden worsening of inﬂammatory
bowel disease. The TPN diet was administered intravenously via a central catheter (a thin tube) for at least one week. Both studies were
generally high quality. Neither study demonstrated any beneﬁcial effects for glutamine. Side effects were not well documented in the
two studies. There were no serious side effects noted in the paediatric study. The study in adult patients reported three central catheter-
related blood infections in the glutamine group compared to none in the non-glutamine control group. Currently, there is insufﬁcient
evidence to allow any ﬁrm conclusions regarding the effectiveness and harms of glutamine for the treatment of active Crohn’s disease.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glutamine-enriched polymeric diet versus standard low-glutamine polymeric diet for induction of remission in Crohn’s disease
Patient or population: Childen (<16 years old)with active Crohn’s disease
Settings: Hospital
Intervention: Glutamine-enriched polymeric diet
Comparison: Standard low-glutamine polymeric diet
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Glutamine-enriched
polymeric diet
Induction of remission at
4 weeks
555 per 10001 444 per 1000
(172 to 1132)
RR 0.80 (0.31 to 2.04) 18
(1 study)
⊕⊕©©
low2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The control group estimate comes from the control arm of the included study on children with active Crohn’s disease.
2 Downgraded two levels due to small sample size and low event rates resulting in serious imprecision (9 events).
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B A C K G R O U N D
Crohn’s disease is a chronic relapsing inﬂammatory condition of
the alimentary tract characterised by gut mucosal inﬂammation,
enhanced pro-inﬂammatory cytokine activity, increased gut per-
meability and poor nutrition secondary to decreased intake and to
increased catabolic losses (Katz 1989) . Glutamine, a conditionally
essential amino acid in catabolic states, is the principal respiratory
substrate for enterocytes (Windmueller 1978). It is known to play
a key role in maintaining the integrity of the intestinal mucosa.
Glutamine supplementation has been shown to reduce intestinal
permeability (Hond 1999), prevent mucosal atrophy and main-
tain gut integrity (Van der Hurst 1993). It spares mobilisation
of glutamine from skeletal muscle and thereby improves nitrogen
balance (Stehle 1989).
Protein turnover is increased in active Crohn’s disease (Thomas
1992), and subjects are in a state of catabolism (Kangas 1986).
Low plasma glutamine levels have been described in patients with
Crohn’s disease (Thomas 1991). This may be due to enhanced
utilisation of glutamine by the diseased intestinal mucosa (Lacey
1990). The body’s requirement for glutamine may exceed the sup-
ply causing a state of glutamine deﬁciency. This nature of condi-
tional essentialness has been demonstrated in other catabolic states
such as burns, trauma and sepsis (Hall 1996).
In experimental animal models of Crohn’s disease, glutamine sup-
plementation prevented macroscopic ileitis and increased intesti-
nal glutathione status (Sido 2006), reduced inﬂammation, pre-
vented weight loss, improved nitrogen balance and reduced dis-
ease activity (Fox 1988). Glutamine has been shown to reduce
bacterial translocation in an animal model (Fujita 2005), which
may have important implications in the setting of gut mucosal in-
ﬂammation as seen in Crohn’s disease. In vitro, glutamine reduces
the production of the pro-inﬂammatory cytokines interleukin-6
and interleukin-8, and enhances the production of the anti-in-
ﬂammatory cytokine, interleukin-10 in human intestinal mucosa
(Coefﬁer 2003). Down-regulation of chemokines by glutamine
could also contribute to its therapeutic potential by reducing in-
testinal inﬂammation during critical illnesses (Marion 2004).
Considering that glutamine may have positive nutritional,
metabolic and immunologic beneﬁts with respect to Crohn’s dis-
ease, it has been trialled for the treatment of people with the dis-
ease (Akobeng 2000). The aim of this systematic review is to sum-
marise the current evidence on the use of glutamine for induction
of remission in Crohn’s disease.
O B J E C T I V E S
1. To evaluate the effectiveness of glutamine supplementation for
induction of remission in Crohn’s disease.
2. To evaluate adverse events associated with glutamine supple-
mentation in Crohn’s disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials were considered for inclusion.
Types of participants
Patients of any age with active Crohn’s disease were considered for
inclusion. Crohn’s disease should have been diagnosed by conven-
tional clinical, radiographic, endoscopic and histological criteria.
Active disease should have been deﬁned using a recognised Crohn’s
disease activity index.
Types of interventions
Randomised controlled trials where glutamine was administered
by any route and compared to placebo, an active comparator, or a
no intervention control group were considered for inclusion.
Types of outcome measures
The primary outcome was clinical or endoscopic remission as de-
ﬁned by the primary studies. Secondary outcomes included clin-
ical response as deﬁned by the primary studies, improvement in
intestinal permeability, quality of life, growth in children, and ad-
verse events.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases from inception to
November 15, 2015:
1. MEDLINE;
2. EMBASE;
3. Cochrane Central Register of Controlled Trials; and
4. The Cochrane IBD Group Specialised Register.
Therewere no language restrictions. The search strategy is reported
in Appendix 1.
Searching other resources
Reference lists from retrieved articles were inspected to identify
additional citations that may have been missed by the electronic
searches.
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Data collection and analysis
Selection of studies
The search results were independently screened by two authors
(MG and ME) to identify potentially relevant studies. Two au-
thors (MG and ME), after reading the full texts, independently
assessed the eligibility of all trials identiﬁed using the pre-speciﬁed
eligibility criteria stated above. Disagreement among authors was
resolved by discussion and agreement was reached by consensus.
Data extraction and management
A data extraction formwas developed and used to extract informa-
tion on relevant features and results of included studies. The form
was based on the Cochrane checklist of items to consider for data
extraction (Higgins 2011a). Two authors (ME andMG) indepen-
dently extracted and recorded data on the predeﬁned checklist.
Extracted data included the following items:
A. Methods (methods of randomisation, allocation concealment,
blinding, inclusion and exclusion criteria, deﬁnition of outcomes);
B. Participants (number, age, gender, disease activity, concurrent
medication);
C. Interventions (formulation, dose, frequency, duration, method
of administration); and
D. Outcomes (clinical remission, intestinal permeability, adverse
events) and time of assessment.
Assessment of risk of bias in included studies
MEandMG independently assessed themethodological quality of
each included study using the Cochrane risk of bias tool (Higgins
2011b). The study features assessed included:
a. Random sequence generation;
b. Allocation concealment;
c. Blinding of participants and personnel;
d. Blinding of outcome assessment;
e. Completeness of outcome data;
f. Selective reporting; and
g. Other sources of bias.
We rated each of these factors as ‘low risk’, ‘high risk’ or ‘unclear
risk’ of bias.
The overall quality of the evidence supporting the primary out-
come was assessed using the GRADE criteria (Guyatt 2008;
Schunemann 2011). The GRADE approach appraises the quality
of a body of evidence based on the extent to which one can be
conﬁdent that an estimate of effect reﬂects the item being assessed.
Randomised trials start as high quality evidence, butmay be down-
graded due to: risk of bias (methodological quality), indirectness
of evidence, unexplained heterogeneity, imprecision (sparse data)
and publication bias. The overall quality of the evidence for each
outcome was determined after considering each of these factors
and graded as:
• High: further research is very unlikely to change conﬁdence
in the estimate of effect;
• Moderate: further research is likely to have an important
impact on conﬁdence in the estimate of effect and may change
the estimate;
• Low: further research is very likely to have an important
impact on conﬁdence in the estimate of effect and is likely to
change the estimate; and
• Very low: any estimate of effect is very uncertain.
Measures of treatment effect
TheCochraneCollaborationReviewManager (RevMan) software
(version 5.3) was used for data analysis. We calculated the risk ra-
tio and corresponding 95% conﬁdence interval (95% CI) for di-
chotomous outcomes using a ﬁxed-effectmodel.We calculated the
mean difference (MD) and corresponding 95%CI for continuous
outcomes measured using the same units. We planned to calculate
the standardised mean difference (SMD) and corresponding 95%
CI for continuous outcomes where different scales were used to
evaluate the same outcome.
Unit of analysis issues
If any trial hadmultiple treatment groups, the ‘shared’ comparison
group was to be divided by the number of treatment groups, and
comparisons between each treatment group and the split compar-
ison group were to be treated as independent comparisons.
Dealing with missing data
Data were analysed according to the intention-to-treat principle.
Patients with ﬁnalmissing outcomeswere assumed to be treatment
failures. A sensitivity analysis was planned to assess the impact on
the results of the assumption of treatment failure when data were
missing.
Assessment of heterogeneity
We planned to assess heterogeneity by visually inspecting forest
plots and by calculating theChi2 test of heterogeneity. A P value of
< 0.10 was considered statistically signiﬁcant. The I2 statistic was
to be calculated to quantify the effect of heterogeneity (Higgins
2003).
An I2 value of:
• < 25% denotes low heterogeneity;
• ≥ 50% denotes moderate heterogeneity; and
• ≥ 75% denotes high heterogeneity.
We planed to use a random-effects model in situations of unex-
plained heterogeneity. When signiﬁcant heterogeneity was iden-
tiﬁed, we planned to examine the included studies for sources of
both clinical and methodological heterogeneity. We planned to
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explore potential explanations for heterogeneity using sensitivity
analysis.
Assessment of reporting biases
If there was an appropriate number of studies in a pooled analysis
(i.e. > 10 studies), we planned to investigate potential publication
bias using funnel plots (trial effects versus trial size).
Data synthesis
Studies were to be pooled for meta-analyses when the interven-
tions, patient groups, outcome measures, and timing of outcome
assessment were sufﬁciently similar (to be determined by consen-
sus).
Subgroup analysis and investigation of heterogeneity
The following pre-speciﬁed subgroup analyses were planned:
a. route of glutamine supplementation;
b. duration of treatment;
c. duration of disease; and
d. disease location (pure colonic disease versus small bowel in-
volvement).
Sensitivity analysis
Sensitivity analyses were to be conducted based on the following:
a. only including patients whose outcome is known (i.e. number
of patients who completed the study used as denominator);
b. random-effects versus ﬁxed-effect models; and
c. study quality.
R E S U L T S
Description of studies
Results of the search
A literature search conducted on November 15, 2015 identiﬁed
168 records. After duplicates were removed, a total of 143 records
remained for review of titles and abstracts. Two authors (AA and
MG) independently reviewed the titles and abstracts of these trials
and seven records were selected for full text review (see Figure
1). Three articles were excluded (See: Characteristics of excluded
studies). Four reports of two trials (total of 42 patients) met the
pre-deﬁned inclusion criteria and were included in the review (
Akobeng 2000; Ockenga 2005).
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Figure 1. Study flow diagram.
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Included studies
Akobeng 2000 was a double-blind randomised controlled trial
conducted at a single centre in the UK. This study randomised 18
patients (< 16 years old) with active Crohn’s disease, deﬁned by a
Paediatric Crohn’s Disease Activity Index (PCDAI) of > 12. Par-
ticipants received either a standard polymeric diet with a low glu-
tamine content (4% of amino acid composition) or a glutamine-
enriched polymeric diet (42% of amino acid composition) for four
weeks as primary therapy for active Crohn’s disease. The two di-
ets were isocaloric and isonitrogenous with an identical essential
amino acid proﬁle. Patients were encouraged to consume the diet
orally. If this was not possible the diet was administered via a ﬁne-
bore nasogastric tube. The primary study outcome was clinical
remission at four weeks, deﬁned as a PCDAI < 10. Secondary out-
comes included changes in clinical and laboratory parameters of
disease activity after four weeks. Exclusion criteria included treat-
ment at entry with prednisolone at doses higher than 5 mg/day,
and treatment with immunosuppressive agents. The use of con-
current medications was not reported. Two patients, both from
the glutamine-enriched diet group, were withdrawn from the trial
because of non-tolerance of the diet. Analysis of remission rates
was performed on an intention-to-treat basis. Data from the same
trial on intestinal permeability and serum antioxidant concentra-
tions were published separately (Akobeng 2000a; Akobeng 2007).
Ockenga 2005 was a randomised controlled trial conducted at
a single centre in Germany. The study randomised 24 adults (>
18 years of age) with acute exacerbation of inﬂammatory bowel
disease (19 Crohn’s disease, 5 ulcerative colitis) who were being
considered for total parenteral nutrition (TPN). Patients in the
glutamine group received 0.3 g/kg/day alanyl-glutamine (result-
ing in 0.2 g/kg/day glutamine) which was added to 1.2 g/kg/day
of standard amino-acid solution. Patients in the control group re-
ceived 1.5 g/kg/day amino acids in a standard solution which did
not contain glutamine. The study investigators, patients, nurses,
and primary physicians were unaware of treatment assignment.
Exclusion criteria included non consent, receipt of TPN within
two weeks of entry, pregnancy, and renal failure. All patients were
treated with mesalazine (dosage not speciﬁed). Ten patients in
the glutamine group received prednisolone (mean dose 0.85 mg/
kg/day ± 0.66), whilst 12 patients in the control group received
prednisolone (mean dose 0.73 mg/kg/day ± 0.20). One patient
in the glutamine group was treated with azathioprine compared
to three patients in the control group. TPN was administered for
at least one week. The primary study outcomes were glutamine
plasma concentrations and intestinal permeability after one week.
Secondary outcomes included protein catabolism, disease activity
measured by the Crohn’s Disease Activity Index (CDAI), infec-
tious complications, and duration of TPN.
See the Characteristics of included studies table for further infor-
mation on the included studies.
Risk of bias in included studies
Both included studies used computer-generated randomisation
codes and sealed opaque envelopes for allocation concealment and
were rated as low risk of bias for these items. The Akobeng 2000
study was rated as low risk of bias for participants and personnel
and for outcome assessors. The study double-blind and the two
diets were not distinguishable in appearance, smell, or taste and the
randomisation codewas not broken until the studywas completed.
There were no drop-outs in Akobeng 2000 and the study was rated
as low risk of bias for incomplete outcome data. Akobeng 2000
reported on all pre-speciﬁed outcomes and was rated as low risk of
bias for selective outcome reporting. There did not appear to be
any other apparent sources of bias and Akobeng 2000 was rated as
low risk of other sources of bias. The Ockenga 2005 study did not
describe methods for blinding of participants and personnel, and
for blinding of outcome assessment and was rated as unclear risk of
bias for these items. Intestinal permeability data were available for
14 of 19 patients with Crohn’s disease in the Ockenga 2005 study.
Incomplete outcomes data was judged to be at low risk of bias.
Ockenga 2005 reported on all pre-speciﬁed outcomes and was
rated as low risk of bias for selective outcome reporting. There did
not appear to be any other apparent sources of bias and Ockenga
2005 was rated as low risk of bias for other sources of bias. The
risk of bias assessment is summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison
See Summary of ﬁndings for the main comparison
Clinical remission: One study investigated this outcome (
Akobeng 2000). There was no statistically signiﬁcant difference
in remission rates between patients who received the glutamine-
enriched diet compared to those who received a standard low glu-
tamine diet. Forty-four per cent (4/9) of patients who received the
glutamine-enriched diet achieved clinical remission (PCDAI <10)
after 4 weeks compared to 56% (5/9) of those who received the
standard low glutamine diet (RR 0.80, 95% CI 0.31 to 2.04; See
Figure 3). A GRADE analysis indicated that the overall quality of
evidence for this outcome was low due to serious imprecision (9
events, see Summary of ﬁndings for the main comparison).
Figure 3. Forest plot of comparison: 1 Glutamine-enriched diet versus standard diet, outcome: 1.1 Clinical
remission.
Endoscopic remission: None of the included studies reported on
this outcome.
Clinical response: None of the included studies reported on this
outcome.
Intestinal permeability: Both trials investigated this outcome.
In Akobeng 2000 the mean lactulose/mannitol permeability ra-
tio decreased from 0.103 to 0.037 in the standard diet group (P
= 0.012) after 4 weeks, and reduced from 0.068 to 0.043 in the
glutamine-supplemented group (P = 0.058). There was no statis-
tically signiﬁcant difference between the two groups with regard
to changes in lactulose/mannitol permeability ratios (P = 0.239).
In Ockenga 2005, the mean lactulose/xylose ratio at baseline was
0.042 ± 0.03 with no difference between patients with Crohn’s
disease or ulcerative colitis (0.043 ± 0.038 versus 0.040 ± 0.027, P
> 0.05). After one week, changes in lactulose/xylose permeability
ratio were not signiﬁcantly different in patients who received glu-
tamine compared to those who did not receive glutamine (MD -
0.01, 95% CI -0.04 to 0.02; See Figure 4).
Figure 4. Forest plot of comparison: 1 Glutamine-enriched diet versus standard diet, outcome: 1.2
Intestinal permeability.
Quality of life: None of the included studies reported on this
outcome.
Growth in children: None of the included studies reported on
this outcome.
Adverse events:The stated purpose of Akobeng 2000 was to com-
pare the efﬁcacy of the glutamine-enriched diet with a standard
low-glutamine diet for the treatment of active Crohn’s disease.
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No speciﬁc adverse event outcomes were reported but the authors
have conﬁrmed that no serious adverse events were noted in either
group (Akobeng, personal communication). In Ockenga 2005,
three central catheter infections with positive blood cultures were
diagnosed in the glutamine group compared to none in the con-
trol group (RR 7.00, 95% CI 0.04 to 124.44; See Figure 5).
Figure 5. Forest plot of comparison: 1 Glutamine-enriched diet versus standard diet, outcome: 1.3 Central
catheter infections.
Other outcomes: Both studies evaluated changes in measures of
disease activity or symptoms. InAkobeng 2000, reduction inmean
PCDAI was signiﬁcantly higher in the control group compared to
the glutamine-enriched group after four weeks but there were no
statistically signiﬁcant differences in changes in platelet count, oro-
somucoid, or weight. In Ockenga 2005, glutamine supplementa-
tion was not associated with any statistically signiﬁcant changes in
CDAI, white cell count, frequency of diarrhoea, pain, or extrain-
testinal symptoms. Ockenga 2005 also reported that the length
of hospital stay did not differ signiﬁcantly between patients who
received glutamine and those who did not. Akobeng 2000 investi-
gated changes in plasma antioxidant concentration. After 4 weeks,
there were no statistically signiﬁcant differences between patients
who received the glutamine-enriched diet compared to those who
received a standard diet with regard to changes in plasma concen-
trations of selenium (P = 0.076), urate (P = 0.053), glutathione
(P = 0.815), vitamin E (P = 0.245), vitamin C (P = 0.639), and
malondialdehyde (P = 0.190). There was however a statistically
signiﬁcant increase in the mean vitamin A level in the standard
diet group compared to the glutamine-enriched diet group (P =
0.018). InOckenga 2005, plasma concentrations of glutamine did
not change signiﬁcantly in either group throughout the study.
D I S C U S S I O N
Summary of main results
Glutamine, the principal respiratory substrate for enterocytes is
known to be important for maintenance of intestinal metabolism,
structure and function. It has therefore been suggested that it may
facilitate the induction of remission in people withCrohn’s disease.
We have found no evidence in this review to suggest that glutamine
supplemention provides any beneﬁt in the treatment of active
Crohn’s disease.
Two trials were included in the review (Akobeng 2000; Ockenga
2005). The study populations, nature of interventions, and the
way outcomes were assessed differed between the two studies and
it was not possible to pool data for meta-analysis. Akobeng 2000
found no statistically signiﬁcant difference in clinical remission
rates betweenpatientswhowere supplementedwith glutamine and
those who were not. Neither study demonstrated any signiﬁcant
changes in intestinal permeability between patients supplemented
with glutamine and those who were not. In Akobeng 2000, the re-
duction in mean PCDAI was signiﬁcantly higher in patients who
received a standard low glutamine diet compared to those who re-
ceived the glutamine-enriched diet. In Ockenga 2005, glutamine
supplementation was not associated with any statistically signiﬁ-
cant differences inCDAI, white cell count, frequency of diarrhoea,
pain, extraintestinal symptoms or length of hospital stay. Neither
study reported data on endoscopic remission, clinical response, or
quality of life.
Adverse event data were not well documented in the included
studies. Akobeng 2000 did not report on any speciﬁc adverse event
outcomes. However, the authors have conﬁrmed that no serious
adverse events were noted in either group. Ockenga 2005 reported
that three catheter infections with positive blood cultures were
diagnosed in the glutamine group compared to none in the control
group. Ockenga 2005 did not report on any other adverse events.
Overall completeness and applicability of
evidence
The results of this systematic review, which are applicable to pa-
tients with active Crohn’s disease, should be interpreted with cau-
tion. Although the results of the included studies did not support
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the hypothesis that glutamine supplementation may be useful in
active Crohn’s disease, both studies were limited by small sample
sizes and serious imprecision. For the primary outcome, induction
of clinical remission, the point estimate of the risk ratio (0.80)
suggests that patients who received the glutamine-enriched poly-
meric diet were 20% less likely to enter remission compared to
patients who received the standard low-glutamine diet. However,
the 95% conﬁdence interval includes both a reduction in likeli-
hood of remission of about 70%, and a two fold increase in the
likelihood of remission (95% CI 0.31 to 2.04). Larger trials are
required to determine if glutamine provides any beneﬁt for induc-
tion of remission in Crohn’s disease.
Quality of the evidence
The Akobeng 2000 study was judged to be at low risk of bias.
Ockenga 2005 id not describe the methods used for blinding of
participants and personnel, or for blinding of outcome assessment
and was rated as unclear risk of bias for these domains. Ockenga
2005 was rated as low risk of bias for the other items.The GRADE
rating for the evidence supporting the primary outcome (clinical
remission) was low because the small sample size and low event
rates resulted in serious imprecision.
Potential biases in the review process
A comprehensive literature search was performed to reduce po-
tential bias and identify all eligible studies. Two review authors
independently assessed studies for inclusion, extracted data and
rated study quality. There are limitations to this review. The two
included studies were small and it was not possible to pool data
for meta-analysis because of signiﬁcant differences in the study
populations, nature of interventions, and the way outcomes were
assessed.
Agreements and disagreements with other
studies or reviews
To our knowledge, there are no other published systematic reviews
that assess the efﬁcacy and safety of glutamine in active Crohn’s
disease.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently there is insufﬁcient evidence to allow ﬁrm conclusions
regarding the efﬁcacy and safety of glutamine for induction of re-
mission in Crohn’s disease. Data from two small studies suggest
that glutamine supplementation may not be beneﬁcial in active
Crohn’s disease but these results need to be interpreted with cau-
tion as they are based on small numbers of patients.
Implications for research
This review highlights the need for high quality, adequately pow-
ered randomised controlled trials to investigate the efﬁcacy and
safety of glutamine for induction of remission in Crohn’s disease.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akobeng 2000
Methods Randomised, double blind, single centre trial
Participants Patients (aged 6-16 years) with active Crohn’s disease deﬁned as a paediatric Crohn’s
disease activity index (PCDAI) higher than 12 (N=18)
Exclusion criteria included treatment at entry with prednisolone at doses higher than
5 mg/day, treatment with immunosuppressive drugs, and unwillingness to provide in-
formed consent
Interventions Exclusive glutamine-enriched polymeric diet (42% of amino acid composition) [n=9]
for 4 weeks
Exclusive standard low glutamine polymeric diet (4% of amino acid composition) [n=
9] for 4 weeks
Outcomes Primary outcome: clinical remission at 4 weeks deﬁned as a PCDAI < 10
Secondary outcomes: changes in PCDAI, changes in inﬂammatory markers, intestinal
permeability, serum antioxidant concentrations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation
Allocation concealment (selection bias) Low risk Assignments in opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind; the two diets were not dis-
tinguishable in appearance, smell, or taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Codes were not broken until the study was
completed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full data reported
Selective reporting (reporting bias) Low risk All outcomes speciﬁed in the methods sec-
tion reported on in the results
Other bias Low risk None apparent
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Ockenga 2005
Methods Randomised, blinded, single centre
Participants Adults with acute exacerbation of inﬂammatory bowel disease (19 Crohn’s disease, 5
ulcerative colitis) who were being considered for TPN (N=24)
Exclusion criteria included: not consenting to the study, on TPN within 2 weeks before
study, being pregnant, having renal failure
Interventions TPN with 1.5g/kg body weight of a standard amino acid [n=12] for at least 1 week
TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-
glutamine [n=12] for at least one week
Outcomes Primary outcomes: Glutamine plasma concentrations, intestinal permeability
Secondary outcomes: disease activity, infectious complications, duration of TPN
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment groups generated by random order se-
quence
Allocation concealment (selection bias) Low risk Assignments in sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Authors say it was blinded but unclear how this
was achieved
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intestinal permeability data were available for 14
of 19 patients with Crohn’s disease
Selective reporting (reporting bias) Low risk All outcomes speciﬁed in the methods section re-
ported on in the results
Other bias Low risk None apparent
TPN: total parenteral nutrition.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Benjamin 2011 Participants did not have active disease
Coefﬁer 2010 Review article
Hond 1999 Participants did not have active disease
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D A T A A N D A N A L Y S E S
Comparison 1. Glutamine-enriched diet versus standard diet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical remission 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Intestinal permeability 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Central catheter infections 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Glutamine-enriched diet versus standard diet, Outcome 1 Clinical remission.
Review: Glutamine for induction of remission in Crohn’s disease
Comparison: 1 Glutamine-enriched diet versus standard diet
Outcome: 1 Clinical remission
Study or subgroup
Glutamine-
enriched
diet Standard diet Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Akobeng 2000 4/9 5/9 0.80 [ 0.31, 2.04 ]
0.01 0.1 1 10 100
Favours standard diet Favours glutamine diet
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Analysis 1.2. Comparison 1 Glutamine-enriched diet versus standard diet, Outcome 2 Intestinal
permeability.
Review: Glutamine for induction of remission in Crohn’s disease
Comparison: 1 Glutamine-enriched diet versus standard diet
Outcome: 2 Intestinal permeability
Study or subgroup
Glutamine-
enriched
TPN Standard TPN
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ockenga 2005 9 0.01 (0.05) 8 0.02 (0.01) -0.01 [ -0.04, 0.02 ]
-0.2 -0.1 0 0.1 0.2
Favours glutamine TPN Favours standard TPN
Analysis 1.3. Comparison 1 Glutamine-enriched diet versus standard diet, Outcome 3 Central catheter
infections.
Review: Glutamine for induction of remission in Crohn’s disease
Comparison: 1 Glutamine-enriched diet versus standard diet
Outcome: 3 Central catheter infections
Study or subgroup
Glutamine-
enriched
TPN Standard TPN Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ockenga 2005 3/12 0/12 7.00 [ 0.40, 122.44 ]
0.02 0.1 1 10 50
Favours glutamine TPN Favours standard TPN
19Glutamine for induction of remission in Crohn’s disease (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Search strategy
PubMed
1. Crohn* disease
2. Crohn disease (MeSH)
3. Regional enteritis
4. Ileitis
5. Ileitis (MeSH)
6. Inﬂammatory bowel disease
7. Inﬂammatory bowel diseases (MeSH)
8. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7
9. Glutamine
10. 8 AND 9
EMBASE
1. crohn disease.mp. or crohn disease/
2. crohn’s disease.mp. or crohn’s disease
3. ileitis.mp. or ileitis/
4. inﬂammatory bowel disease.mp. or enteritis/ or inﬂammatory bowel disease
5. 1 or 2 or 3 or 4
6. Glutamine/ or glutamine.mp.
7. 5 and 6
Cochrane Central Register of Controlled Trials
1. Crohn’s disease
2. Crohn disease
3. inﬂammatory bowel disease
4. 1 or 2 or 3
5. glutamine
6. 4 and 5
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we planned to contact leaders in the ﬁeld to identify applicable studies. This was not undertaken. In line with current
Cochrane Collaboration recommendations, we assessed the methodological quality of each included study using the risk of bias tool
(Higgins 2011b) instead of the Jadad scale mentioned in the original protocol. We also assessed the quality of the overall evidence
supporting the primary outcome using the GRADE approach (Guyatt 2008; Schunemann 2011). In addition to the outcomes pre-
speciﬁed in the protocol, we also reported on other outcomes mentioned in the included primary studies.
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